Binds Expression Product Or Fragment Thereof Of Cancer-related Gene (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 424/138.1)
  • Patent number: 10501555
    Abstract: The present invention refers to humanized anti-Trop-2 antibodies and their fragments, derivatives and conjugates that are able to recognise and bind with high affinity distinct regions of the Trop-2 molecule. The present invention also teaches the use of such antibodies and of pharmaceutical compositions thereof for diagnosis and therapy of human pathologies, in particular cancer.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: December 10, 2019
    Assignee: ABRUZZO THERANOSTIC S.R.L.
    Inventors: Emanuela Guerra, Saverio Alberti
  • Patent number: 10398688
    Abstract: The invention relates to a combination of an immunomodulatory imide drug (IMiD) and an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a subject. It further relates to an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a patient, wherein the patient is IMiD resistant. It further relates to a method of monitoring the efficacy of an IMiD treatment regimen by comparing the protein level of CD147 and/or MCT1 in samples obtained from a subject prior and during IMiD treatment.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: September 3, 2019
    Assignee: KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MÜNCHEN
    Inventors: Florian Bassermann, Ruth Eichner, Vanesa Fernandez-Saiz
  • Patent number: 10392398
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: August 27, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • Patent number: 10378061
    Abstract: A method of predicting an effect of an anti-c-Met antibody and/or selecting a subject for application of an anti-c-Met antibody including measuring a level of the biomarker in a biological sample, is provided.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: August 13, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jongsuk Chung, Tae Jin Ahn, Dae-Soon Son, Eunjin Lee
  • Patent number: 10288621
    Abstract: A method to detect local antibodies such as antigen-specific IgE via a brush biopsy specimen of a mucosal surface of a subject is disclosed. The method is easily performed in an office setting on both adult and pediatric patients. Also disclosed is a brush device specially designed for harvesting materials from a mucosal surface such as the medial surface of the inferior turbinate.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: May 14, 2019
    Assignee: Cornell University
    Inventor: William Reisacher
  • Patent number: 10208357
    Abstract: The present invention relates to cell-based assays involving HER2. The assays use assay cells that are transfected with cassettes containing the HER2 gene of interest and measure the effect of mutations on the activity of HER2, and on their response to inhibitors.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: February 19, 2019
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventor: Yick Loi Raymond Yu
  • Patent number: 10139394
    Abstract: The present invention relates to a novel function of lysyl tRNA synthetase, that is, lysyl tRNA synthetase interacts with 67LR through translocation of KRS into plasma membrane, and so enhances tumor (or cancer) cell migration, thereby having an effect on cancer metastasis. More specifically, it relates to method for controlling cancer metastasis or cancer cell migration by modulating an cellular level of lysyl tRNA synthetase, an use of an expression vector comprising a construct inhibiting KRS expression for preventing or treating cancer, an use of an agent inhibiting KRS activity for preventing or treating cancer, a method for screening an agent which modulates cancer metastasis or cancer cell migration, a method for screening an agent inhibiting an interaction between KRS and 67LR. Accordingly, cancer metastasis and cancer cell migration may be controlled using the inventive KRS, further the cellular metabolism related to laminin receptor (67LR) of plasma membrane may be controlled.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: November 27, 2018
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Jin Woo Choi
  • Patent number: 10119122
    Abstract: The disclosure is concerned among others with means and methods for obtaining endothelial cells and to means and methods for in vitro cell culture comprising endothelial cells and pericytes and/or smooth muscle cells derived from the pericytes. The endothelial cells or the pericytes and/or smooth muscle cells, or both, are preferably derived from in vitro differentiated pluripotent stem cells.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: November 6, 2018
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN
    Inventors: Christine Lindsay Mummery, Valeriya Viktorovna Orlova
  • Patent number: 10112977
    Abstract: Provided are a synthetic peptide having a multinucleation-inducing activity that can cause multinucleation in a target cell, a multinucleation-inducing agent containing this peptide, and a multinucleation induction method that uses this peptide. The synthetic peptide provided by the present invention is an artificially synthesized peptide that contains (A) a membrane-permeable peptide sequence and (B) a multinucleation-inducing peptide sequence, and that can cause multinucleation in at least one type of eukaryotic cell of human origin or non-human mammal origin. The multinucleation-inducing peptide sequence is constituted of an amino acid sequence given by SEQ ID NO: 1 or SEQ ID NO: 2 or a modified amino acid sequence therefrom.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: October 30, 2018
    Assignees: Toagosei Co., Ltd., National University Corporation Nagoya University
    Inventors: Nahoko Baileykobayashi, Tetsuhiko Yoshida, Makoto Sawada
  • Patent number: 10030071
    Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: July 24, 2018
    Assignees: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.
    Inventors: Kazuhiro Morishita, Kazuko Kaneda, Yoshikazu Kurosawa, Gene Kurosawa, Katsuyuki Mitomo, Katsushi Kouda, Yoshinori Ukai
  • Patent number: 9969811
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: May 15, 2018
    Assignee: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Patent number: 9950077
    Abstract: The present disclosure provides anti-folate receptor alpha (FRA) antibody-drug conjugates comprising a hydrophilic self-immolative linker. The present disclosures further provide compositions and methods for treating cancers.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: April 24, 2018
    Assignees: BIOALLIANCE C.V., ABGENOMICS INTERNATIONAL INC.
    Inventors: Rong-Hwa Lin, Shih-Yao Lin, Yu-Chi Hsieh, Chiu-Chen Huang, Shu-Hua Lee, Yu-Ying Tsai, Feng-Lin Chiang, Li-An Hu
  • Patent number: 9932410
    Abstract: The invention relates to human neutralizing anti-KIT antibodies and uses thereof. More particularly, the invention relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 2 in the H-CDR1 region, SEQ ID NO: 3 in the H-CDR2 region and SEQ ID NO: 4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO: 7 in the L-CDR2 region and SEQ ID NO: 8 in the L-CDR3 region. The invention also relates to an antibody comprising a heavy chain variable region comprising SEQ ID NO: 10 in the H-CDR1 region, SEQ ID NO: 11 in the H-CDR2 region and SEQ ID NO: 12 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 14 in the L-CDR1 region, SEQ ID NO: 15 in the L-CDR2 region and SEQ ID NO: 16 in the L-CDR3 region.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: April 3, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier, Universite Paris- Sud, Institut Regional du Cancer du Montpellier, Ecole Normale Superieure de Cachan
    Inventors: Marie-Alix Poul, Mariane Le Gall, Ronan Crepin
  • Patent number: 9901594
    Abstract: Pharmaceutical compositions containing a combination of NPM inhibitor and anti-cancer agent are disclosed. Methods of inhibiting or reducing the growth of cancer cells in a subject, by administering an effective amount of nucleophosmin (NPM) inhibitor and one or more anti-cancer agents, whereby the symptoms and signs of cancer in the subject are reduced are also provided.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: February 27, 2018
    Assignees: CHANG GUNG MEMORIAL HOSPITAL
    Inventor: Sen-yung Hsieh
  • Patent number: 9828643
    Abstract: Diagnostic assays for medically classifying cancer patients are provided. The method comprises assessing a tissue sample of the patient for the presence of a copy number gain of chromosome regions 1q23.3 and/or 1q21.2. Copy number gain of chromosome regions 1q23.3 and/or 1q21.2 is indicative of a less favorable prognosis as compared to the prognosis if there was no copy number gain in the same regions.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: November 28, 2017
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Jonathan E. Rosenberg, Joaquim Bellmunt, Philip Kantoff, Massimo Loda
  • Patent number: 9828424
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: November 28, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 9815904
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: November 14, 2017
    Assignee: Genetech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Patent number: 9789203
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 17, 2017
    Assignee: Novartis AG
    Inventors: Tinya Abrams, Steven Cohen, Christie P. Fanton, Catrin Finner, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette
  • Patent number: 9745377
    Abstract: The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto. In particular, the antibodies that react immunologically with a particular epitope found in anti-tumor antigen antibodies are not only indicative of favorable therapy using the anti-tumor antigen antibodies, but are therapeutic in and of themselves.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: August 29, 2017
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Paula R. Pohlmann, Raymond L. Mernaugh, Carlos L. Arteaga
  • Patent number: 9730926
    Abstract: Pharmaceutical composition including a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor and a method of preventing and/or treating cancer including co-administering a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject in need thereof.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: August 15, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Powei Lin, Kwang Ho Cheong, Young Jun Koh, Jae-woong Hwang, Seung Hyun Lee, Jung Wook Lee
  • Patent number: 9717715
    Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: August 1, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seung Hyun Lee, Geun Woong Kim, Kyung Ah Kim, Hye Won Park, Ho Yeong Song, Young Mi Oh, Saet Byoul Lee, Ji Min Lee, Kwang Ho Cheong, Yun Ju Jeong, Mi Young Cho, Jae Hyun Choi, Yun Jeong Song, Yoon Aa Choi
  • Patent number: 9707250
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least three saturated or unsaturated, linear or branched hydrocarbon chains comprising from 2 to 30 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 18, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE BORDEAUX, Université d' Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre Régional de Lutte Contre le Cancer, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Arnaud Gissot, Palma Rocchi, Julie Acunzo
  • Patent number: 9701962
    Abstract: The present invention concerns an oligonucleotide modified by substitution at the 3? or the 5? end by a moiety comprising at least one ketal functional group, wherein the ketal carbon of said ketal functional group bears two saturated or unsaturated, linear or branched, hydrocarbon chains comprising from 1 to 22 carbon atoms, and the use therefore as a medicament, in particular for use for treating cancer.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: July 11, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE BORDEAUX, UNIVERSITE D 'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Philippe Barthelemy, Khalid Oumzil, Palma Rocchi, Julie Acunzo
  • Patent number: 9701740
    Abstract: Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: July 11, 2017
    Assignees: YALE UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The United States of America represented by the Department of Veterans Affairs
    Inventors: James E. Hansen, Peter M. Glazer, Richard H. Weisbart, Robert N. Nishimura, Grace Chan
  • Patent number: 9684000
    Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 20, 2017
    Assignee: GENENTECH, INC.
    Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
  • Patent number: 9676865
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: June 13, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: John A. Lewicki, Austin L. Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
  • Patent number: 9589100
    Abstract: A method of computing the risk profile of a neoplastic tissue in a patient is disclosed. The method includes the steps of (a) processing a sample of tumor tissue or cancer cells from the patient in a form suitable for visualization and demarcation of cell nuclei, individually distinguishable centrosomes (iCTRs) and megacentrosomes (mCTRs) in a region of interest (ROI) defined by a plurality of cell nuclei; (b) determining the numbers of iCTRs and mCTRs associated with each cell nucleus in the ROI; (c) determining the volume of each iCTR and mCTR in the ROI; and (d) calculating one or more centrosome amplification scores (CASs) values for the sample based on steps (b) and (c), wherein the one or more CASs indicate the severity of centrosome amplification, the frequency of centrosome amplification, or both, and wherein the one or more scores provide a measure of a level of risk and/or a prognosis associated with the neoplastic tissue.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: March 7, 2017
    Assignee: NOVAZOI THERANOSTICS
    Inventors: Ritu Aneja, Padmashree C. G. Rida
  • Patent number: 9546218
    Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: January 17, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Gavin Thurston
  • Patent number: 9527907
    Abstract: Specific binding members that bind the ED-A isoform of fibronectin for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, and/or for use in delivery to the neovasculature of endometriotic tissue of a molecule conjugated to the specific binding member. Specific binding members that bind tenascin-C, especially the A1, A2, A3, A4 and/or D domain tenascin-C large isoform, for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, psoriatic arthritis or psoriasis, and/or for use in delivery to the neovasculature of endometriotic, psoriatic arthritic or psoriatic tissue of a molecule conjugated to the specific binding member.
    Type: Grant
    Filed: December 28, 2009
    Date of Patent: December 27, 2016
    Assignee: Philogen S.P.A.
    Inventor: Kathrin Schwager
  • Patent number: 9511085
    Abstract: The present invention relates to a novel function of lysyl tRNA synthetase (KRS) which enhances tumor cell migration and affects cancer metastasis via KRS's interaction with laminin receptor (67LR) by its translocation to membrane. More particularly, the present invention relates to a method for modulating cancer metastasis or migration, which comprises regulating intracellular levels of KRS; a composition for preventing or treating cancer; use of expression vector for inhibiting the expression of KRS; a method for preventing or treating cancer; use of an agent for inhibiting an activity of KRS; a method for screening an agent which modulates cancer metastasis or migration; and a method for screening an agent which inhibits the interaction of KRS with 67LR, by said novel function. Thus, KRS can modulate cancer metastasis or migration and furthermore, can modulate intracellular metabolism related to 67LR.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: December 6, 2016
    Assignee: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon Kim, Jin Woo Choi
  • Patent number: 9487591
    Abstract: Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: November 8, 2016
    Assignees: KYOWA HAKKO KIRIN CO., LTD, Kyushu University, National University Corporation
    Inventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
  • Patent number: 9448239
    Abstract: The present invention provides and includes monoclonal antibodies specific or preferentially selective for PCBP-1 antigens, as well as methods utilizing these antibodies to determine the severity of breast cancer in a patient.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: September 20, 2016
    Assignee: ALPER BIOTECH LLC
    Inventor: •gze Alper
  • Patent number: 9417243
    Abstract: The present invention is related to the anti-PAX8 antibodies, kits, cocktails, and use of anti-PAX8 antibodies for detection of cancer.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: August 16, 2016
    Assignee: Biocare Medical, LLC
    Inventors: Weimin Qi, David Tacha
  • Patent number: 9399779
    Abstract: Provided are alternative splicing constructs and methods for their use. In particular, CD44 based alternative splicing constructs are provided that include CD44 exon 5. These alternative splicing constructs are useful in high-throughput assays for testing the effects of compounds on splicing and for achieving targeted cell death.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: July 26, 2016
    Assignee: The Corporation of Mercer University
    Inventors: Dayle A. Daines, Robert J. McKallip
  • Patent number: 9340615
    Abstract: An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the present invention have high antitumor activity, and are useful as agents for decreasing the AXL expression level, antitumor agents, and diagnostic agents for cancer.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: May 17, 2016
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Atsuhiko Maeda, Hajime Miyamoto, Taichi Kuramochi, Atsushi Matsuo, Tomoyuki Igawa, Hirotake Shiraiwa, Hiroyuki Tsunoda, Tatsuhiko Tachibana
  • Patent number: 9316654
    Abstract: We provide an anti-TAZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of TAZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of TAZ in the cell.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 19, 2016
    Assignee: Agency For Science, Technology and Research (A*STAR)
    Inventors: Wanjin Hong, Siew Wee Chan
  • Patent number: 9308278
    Abstract: Antibody drug conjugates (ADC's) that bind to 161P2F10B protein are described herein. 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: April 12, 2016
    Assignee: Agensys, Inc.
    Inventors: Michael Torgov, Robert Kendall Morrison, Aya Jakobovits, Jean Gudas, Zili An
  • Patent number: 9249188
    Abstract: The present Invention relates to nanopeptides isolated from mammalian colostrums with vaccine like antiviral and immunodulator activity via building body's own immune system and attachment inhibition on the cell surface receptors.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: February 2, 2016
    Inventor: Pawan Saharan
  • Patent number: 9187566
    Abstract: Aspects of the present invention provide novel Mig-7 encoding nucleic acids and Mig-7 polypeptides, recombinant DNA expression systems and host cells containing same, as well as methods of inhibiting expression of the subject nucleic acid molecules, inhibiting production of the encoded proteins or polypeptides, inhibiting metastasis of a carcinoma cell in a subject (including in humans), inhibiting migration/invasion of and mimicking of normal cells by carcinoma cells in a subject, detecting the presence of a cancer cell (e.g., a migrating/invading cancer cell or carcinoma cell mimic, and tumor neovascularization) in a sample of a subject's tissue or body fluids, and inhibiting the migration/invasion of or endothelial cell mimicking by a placental cell into the blood stream or vessels of a female mammal.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: November 17, 2015
    Inventor: J. Suzanne Lindsey
  • Patent number: 9090698
    Abstract: Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: July 28, 2015
    Assignee: The University of North Carolina at Charlotte
    Inventor: Pinku Mukherjee
  • Patent number: 9067995
    Abstract: The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: June 30, 2015
    Assignee: UCB PHARMA S.A.
    Inventor: Terence Seward Baker
  • Patent number: 9040049
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and/or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of ADAM 15 and to immunogenic peptide(s) that elicits such antibodies. The invention also relates to compositions and kits comprising the antibodies and immunogenic peptide(s) of the invention, as well as methods and uses of the antibodies and antigen-binding fragments thereof and immunogenic peptide(s), as well as siRNA molecules.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: May 26, 2015
    Assignee: Vasgen Limited
    Inventors: Salman Rahman, Yatin Patel, Holger Gerhardt, Andrea Emma Lundkvist
  • Patent number: 9040041
    Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: May 26, 2015
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, John O. Richards, Gregory L. Moore, David F. Carmichael
  • Patent number: 9029513
    Abstract: A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in the extracellular domain of EGFR.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: May 12, 2015
    Assignees: Toagosei Co. Ltd., Keio University
    Inventors: Nobuyoshi Shimizu, Atsushi Takayanagi, Tetsuhiko Yoshida
  • Patent number: 9028817
    Abstract: The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: May 12, 2015
    Assignee: Glaxo Group Limited
    Inventors: Inusha De Silva, Armin Sepp, Adriaan Allart Stoop
  • Publication number: 20150125452
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: Timothy R. Wilson, Hartmut Koeppen, Mark Merchant, Jeffrey Settleman
  • Publication number: 20150125449
    Abstract: Provided herein are monovalent antibody constructs. In specific embodiments is a monovalent antibody construct comprising: an antigen-binding polypeptide construct which monovalently binds an antigen; and a dimeric Fc polypeptide construct comprising a CH3 domain, said construct comprising two monomeric Fc polypeptides, wherein one said monomeric Fc polypeptide is fused to at least one polypeptide from the antigen-binding polypeptide construct. These therapeutically novel molecules encompass monovalent constructs that display an increase in binding density and Bmax (maximum binding at a target to antibody ratio of 1:1) to a target cell displaying said antigen as compared to a corresponding monospecific bivalent antibody construct with two antigen binding regions. Provided herein are methods for creation of monovalent antibody constructs that shows superior effector efficacy as compared to the corresponding bivalent antibody construct at equimolar concentrations.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 7, 2015
    Inventors: Gordon Yiu Kon Ng, Surjit Bhimarao Dixit, Thomas Spreter Von Kreudenstein
  • Publication number: 20150118154
    Abstract: The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer.
    Type: Application
    Filed: January 8, 2015
    Publication date: April 30, 2015
    Inventors: Marco Alifano, Patricia Forgez
  • Patent number: 9017676
    Abstract: The use of trifunctional bispecific antibodies for the preparation of a pharmaceutical composition for the prophylaxis and treatment of tumor diseases is provided. Trifunctional bispecific antibodies bind to tumor-associated antigens including Her2/neu, CD20, EpCAM, G250, proteoglycans, GD3. GD2, MHC II, EGF-R and CEA expressed on tumor cells at low to medium expression levels. Also provided are methods for the treatment or prophylaxis of tumor diseases by administering a pharmaceutically effective amount of a trifunctional bispecific antibody to a patient in need thereof.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: April 28, 2015
    Inventor: Horst Lindhofer
  • Patent number: RE45968
    Abstract: It is described a vector suitable for efficient selection and/or maturation of a recombinant antibody characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 12, 2016
    Assignee: SIGMA TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
    Inventors: Olga Minenkova, Emiliano Pavoni